Compositions and methods for treating bleeding disorders

JP2023552281A5Pending Publication Date: 2024-11-22BAND THERAPEUTICS LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023528376
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-06-30
Filing Date
2021-11-24
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Current treatments for bleeding disorders such as hemophilia A and von Willebrand disease (VWD) are limited by the short half-life of coagulation factors VIII and von Willebrand factor (VWF), requiring frequent intravenous infusions and are costly, with patients still at risk for severe bleeding episodes and chronic joint damage.

Method used

Administration of VWF-targeting agents, such as PEGylated aptamers, that bind to VWF to increase circulating levels and extend the half-life of VWF and FVIII, thereby stabilizing the FVIII-VWF complex and reducing the frequency of treatments.

Benefits of technology

The VWF-targeting agents significantly increase VWF and FVIII levels in the blood, providing a sustained therapeutic effect with reduced dosing frequency and minimizing bleeding risks, while being well-tolerated with no off-target effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure relates to the treatment of bleeding disorders, particularly hemophilia A (mild, moderate, or severe hemophilia), and von Willebrand disease (VWD), types 1, 2, or 3, using VWF-targeting agents, such as the PEGylated anti-VWF aptamer, BT200.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application Nos. 63 / 117,545, filed November 24, 2020, 63 / 155,012, filed March 1, 2021, and 63 / 216,601, filed June 30, 2021, the contents of each of which are incorporated herein by reference in their entirety.

[0002] Reference to sequence listing This application is filed with an electronic Sequence Listing. The Sequence Listing is provided as a file entitled 20591009PCTSEQLST.txt, created on November 24, 2021, and is 40,029 bytes in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.

[0003] Technical Field The present disclosure relates to agents, compositions, and methods for the treatment of bleeding disorders, such as inherited bleeding disorders (e.g., hemophilia A and von Willebrand disease (VWD)). The methods use agents that bind to VWF and pharmaceutical compositions and formulations thereof. [Background technology]

[0004] Bleeding disorders are a heterogeneous group of conditions in which blood does not clot properly. As a result, patients with bleeding disorders experience heavy bleeding after injury, trauma, or surgery. Some patients may develop severe idiopathic bleeding. Bleeding disorders can be inherited or acquired. Inherited bleeding disorders are often caused by deficiencies of factors involved in blood clotting (i.e., clotting factors, also known as coagulation factors) and abnormalities of blood vessels and platelets. Inherited bleeding disorders caused by deficiencies in coagulation proteins include hemophilia A and B, von Willebrand disease (VWD) types 1, 2 (including subtypes 2a, 2b, 2m, and 2n), and 3, as well as other rare bleeding disorders. Platelet-mediated bleeding disorders include hereditary thrombocytopenia, a condition characterized by low platelet counts, Bernard-Soulier syndrome, and Glanzmann thrombasthenia.

[0005] Blood coagulation is a complex process involving the sequential interaction of a series of components, particularly fibrinogen, factor II (FII), factor V (FV), factor VII (FVII), factor VIII (FVIII), factor IX (FIX), factor X (FX), factor XI (FXI), factor XII (FXII), and von Willebrand factor (VWF). The coagulation components interact with platelets in the blood to maintain normal hemostasis.

[0006] Deficiency of any of the coagulation components and / or disruption of the regulation between coagulation components and platelets can result in bleeding disorders. Genetic defects in coagulation factors, such as mutations in the genes encoding these factors, can cause rare inherited bleeding disorders, such as hemophilia. Hemophilia is an X-linked inherited bleeding disorder that occurs in approximately 1 in 10,000 live births. Hemophilia is caused by a deficiency of coagulation factor VIII (FVIII) (hemophilia A) or factor IX (FIX) (hemophilia B) (reviewed, for example, by Samuelson et al., Blood Rev., 2019, 35:43-50). Mutations in the gene encoding FVIII can result in hemophilia A. Clinical symptoms of hemophilia A are typically characterized by episodes of spontaneous and persistent bleeding ranging from mild to moderate to severe.

[0007] Von Willebrand factor (VWF), a large plasma glycoprotein, circulates in plasma and plays an important role in normal hemostasis. VWF mediates platelet adhesion to exposed subendothelial collagen at sites of vascular injury, promoting platelet-mediated plug formation. VWF also fulfills its hemostatic function by binding to factor VIII (FVIII) and to platelet surface glycoproteins, localizing FVIII to the platelet plug site and subsequent clot formation. VWF complexed with FVIII also stabilizes the FVIII protein in plasma and protects it from proteolysis by activated protein C in the circulation. Thus, the FVIII-VWF complex extends the circulating lifetime of FVIII.

[0008] Deficiency and / or deficiency of VWF can result in von Willebrand disease (VWD). The most common symptoms of VWD include mucocutaneous bleeding, hematomas, and bleeding after trauma or surgery, similar to those of hemophilia A, due to the rapid degradation of FVIII caused by a deficiency of the VWF cofactor. VWD is the most common inherited bleeding disorder, with an estimated prevalence of approximately 1%. Clinically relevant bleeding symptoms are present in approximately 1:10,000 individuals. VWD can be caused by quantitative and / or qualitative deficiencies of VWF. Quantitative VWF deficiency is often associated with severe types 1 and 3 VWD. Type 2 VWD is usually caused by qualitative deficiencies of VWF (i.e., functional deficiencies of VWF). For example, type 2b VWD is characterized by increased binding affinity of VWF to platelet glycoprotein Ib, leading to VWF consumption and thrombocytopenia in some VWD patients with a resulting severe bleeding phenotype.

[0009] Currently, hemophilia A is treated with protein replacement therapy using either plasma-derived or recombinant FVIII. While FVIII replacement / replacement can significantly improve the lifespan of patients with hemophilia, hemophilia patients remain at risk for severe bleeding episodes and chronic joint damage, as preventive treatment is limited by the short half-life, limited availability, and high cost of purified FVIII protein. Treatment and prevention of bleeding in VWD patients focuses on increasing plasma VWF and FVIII levels to adequate hemostatic levels. Current treatments include administration of desmopressin (DDAVP) and stimulating the release of endogenous VWF by infusion of VWF-containing factor concentrates (e.g., VWF / FVIII concentrates) or recombinant VWF preparations. The choice of treatment depends on the type of disease and the severity of the bleeding. Summary of the Invention [Problem to be solved by the invention]

[0010] The present disclosure provides VWF targeting agents for treating bleeding disorders, particularly hemophilia A (including mild, moderate, and severe hemophilia), and von Willebrand disease (VWD) types 1, 2 (e.g., types 2a, 2b, 2m, and 2n), and 3. The VWF targeting agents include VWF-binding aptamers and variants thereof. [Means for solving the problem]

[0011] In one aspect of the present disclosure, a method for treating a bleeding disorder in a patient is provided, the method comprising administering to the patient a pharmaceutically effective amount of a composition comprising a VWF targeting agent. According to the present disclosure, the patient has been diagnosed with a bleeding disorder. The bleeding disorder is an inherited bleeding disorder, including hemophilia A (e.g., mild, moderate, or severe hemophilia), VWD (e.g., VWD types 1, 2a, 2b, 2m, and 2n, and VWD type 3), inherited thrombocytopenia, and rare bleeding disorders. The bleeding disorder may also be acquired, for example, inhibitor-induced thrombocytopenia. In one embodiment, the patient has been diagnosed with hemophilia A. The patient may have mild hemophilia, moderate hemophilia, or severe hemophilia. In another embodiment, the patient has been diagnosed with VWD type 1, VWD type 2 (such as VWD types 2a, 2b, and 2n), or VWD type 3.

[0012] In some embodiments, the VWF targeting agent is a VWF binding agent that binds to VWF. The VWF targeting agent is an antibody, a nanobody, a peptide, an oligonucleotide, RNA (e.g., siRNA, microRNA), a synthetic polynucleotide (e.g., an aptamer), or a small molecule.

[0013] In some embodiments, the VWF-binding agent is a synthetic polynucleotide selected from SEQ ID NO: 3, BT99 (SEQ ID NO: 4), BT100 (SEQ ID NO: 5), BT200 (SEQ ID NO: 6), ARC15105 (SEQ ID NO: 7), ARC1779 (SEQ ID NO: 8), or a variant thereof.

[0014] In some embodiments, a patient with a bleeding disorder may receive a single dose or multiple doses of a VWF targeting agent, hi one embodiment, a patient receives multiple doses of a VWF binding agent.

[0015] In one preferred embodiment, the VWF targeting agent is BT200, a PEGylated aptamer that specifically binds to the A1 domain of human VWF. In one embodiment, BT200 is administered at a dose ranging from 1.0 mg to 10.0 mg, or from 1.0 mg to 6.0 mg.

[0016] In another aspect, the present disclosure provides a method for increasing circulating levels of VWF in the blood system of a subject. The method includes administering to the subject a composition comprising a VWF targeting agent. The VWF targeting agent binds to VWF and increases circulating VWF levels. In some embodiments, the VWF targeting agent is a VWF-binding agent that binds to VWF. As a non-limiting example, the VWF-binding agent is a synthetic polynucleotide selected from SEQ ID NO: 3, BT99 (SEQ ID NO: 4), BT100 (SEQ ID NO: 5), BT200 (SEQ ID NO: 6), ARC15105 (SEQ ID NO: 7), ARC1779 (SEQ ID NO: 8), or a variant thereof. In a preferred embodiment, the VWF targeting agent is BT200, a PEGylated aptamer that specifically binds to the A1 domain of human VWF. BT200 is administered at a dose ranging from 1.0 mg to 10.0 mg, or from 1.0 mg to 6.0 mg. In some embodiments, the subject has been diagnosed with VWD, e.g., VWD type 1, VWD type 2 (including types 2a, 2b, and 2n), and VWD type 3. In other embodiments, the subject has been diagnosed with VWD, including types 1, 2, and 3, and is receiving factor replacement therapy.

[0017] In another aspect, the present disclosure provides a method for extending the circulating lifespan of FVIII in a subject's blood system. The method includes administering to the subject a composition comprising a VWF targeting agent. The VWF targeting agent binds to VWF and increases circulating FVIII levels. In some embodiments, the VWF targeting agent is a VWF-binding agent that binds to VWF. As a non-limiting example, the VWF-binding agent is a synthetic polynucleotide selected from SEQ ID NO: 3, BT99 (SEQ ID NO: 4), BT100 (SEQ ID NO: 5), BT200 (SEQ ID NO: 6), ARC15105 (SEQ ID NO: 7), ARC1779 (SEQ ID NO: 8), or a variant thereof. In a preferred embodiment, the VWF-targeting agent is BT200, a PEGylated aptamer that specifically binds to the A1 domain of human VWF. BT200 is administered at a dose ranging from 1.0 mg to 10.0 mg, or from 1.0 mg to 6.0 mg. In some embodiments, the subject has been diagnosed with hemophilia A, e.g., mild, moderate, or severe hemophilia. In some examples, the subject has been diagnosed with hemophilia A and is receiving factor replacement therapy. In other embodiments, the subject has been diagnosed with VWD type 1, or VWD type 2 (including types 2a, 2b, and 2n), or VWD type 3. In some examples, the subject has been diagnosed with VWD and is receiving VWF replacement therapy. [Brief explanation of the drawings]

[0018] [Figure 1] FIG. 1 shows the additive effect of co-administration of BT200 and desmopressin on VWF and FVIII levels in healthy volunteers. [Figure 2] FIG. 2 is a histogram showing platelet counts after subcutaneous injection of BT200 in patients with type 2b VWD. [Figure 3] FIG. 3 shows the increase in FVIII levels and activity (aPTT FS) in patients with type 2b VWD after subcutaneous injection of BT200. [Figure 4A] FIG. 4A shows the increase in VWF levels after subcutaneous injection of BT200. [Figure 4B]FIG. 4B shows increased VWF activity after subcutaneous injection of BT200 in type 2b VWD patients. [Figure 5] FIG. 5 shows the increase (%) in factor VIII activity after BT200 prophylactic treatment in patients with mild hemophilia A. DETAILED DESCRIPTION OF THE INVENTION

[0019] The details of one or more embodiments of the present disclosure are set forth in the accompanying description below. Although any materials and methods similar or equivalent to those described herein can be used in practicing or testing the present disclosure, the preferred materials and methods are described herein. Other features, objects, and advantages of the present disclosure will be apparent from the description. In the description, the singular also includes the plural unless the context clearly dictates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. In case of conflict, the present specification will control.

[0020] The present disclosure relates to methods, agents, and pharmaceutical compositions and formulations thereof for treating bleeding disorders, such as inherited bleeding disorders (e.g., hemophilia A and VWD). The method for treating a bleeding disorder in a patient includes administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising an agent that targets von Willebrand factor (VWF).

[0021] In particular, the agent herein relates to any molecule capable of targeting VWF in the blood. The VWF targeting agent can bind to VWF and mediate VWF hemostatic function. The VWF targeting agent may be an antibody, nanobody, peptide, oligonucleotide, RNA (e.g., siRNA, microRNA), aptamer and its variants, or small molecule. According to the present disclosure, the VWF targeting agent is a synthetic polynucleotide derived from an aptamer that specifically binds to VWF. The targeting agent may be further modified with one or more chemical modifications and conjugates. The agent and VWF complex protects circulating VWF from clearance, thereby increasing VWF and FVIII levels in the blood and increasing coagulation.

[0022] definition In order to more clearly and concisely describe the subject matter of the claimed disclosure, the following definitions of specific terms are provided, which are used in the following description and the appended claims. Throughout this specification, instances of specific terms should be considered as non-limiting examples.

[0023] Pharmaceutical composition: As used herein, the term "pharmaceutical composition" is sometimes used interchangeably with the term "pharmaceutical formulation." It refers to a combination of an active compound with a pharmaceutically acceptable carrier or excipient, inert or active, that makes the composition suitable for diagnostic or therapeutic use in vitro, in vivo, or ex vivo. In the context of this disclosure, the active compound may be one or more compounds that can be used to treat bleeding disorders.

[0024] Pharmaceutically acceptable excipient: As used herein, the term "pharmaceutically acceptable excipient" refers to a carrier or excipient that is generally safe, non-toxic, and not biologically or otherwise undesirable and is useful for preparing pharmaceutical compositions, including carriers or excipients acceptable for veterinary and human pharmaceutical use. As used in the specification and claims, "pharmaceutically acceptable carrier or excipient" includes one or more such carriers or excipients. As used herein, the term "pharmaceutically acceptable carrier" encompasses standard pharmaceutical carriers such as phosphate-buffered saline, water, and emulsions (such as oil / water or water / oil emulsions), as well as any of various types of wetting agents. In some examples, compositions and formulations may also include stabilizers and preservatives. The term "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and generally do not produce adverse reactions when administered to humans. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a federal or state government regulatory agency for use in animals, more particularly humans, or listed in the United States Pharmacopoeia or other generally recognized pharmacopeia, or generally recognized as safe for use in parenteral products.

[0025] Therapeutically effective amount: As used herein, the term "therapeutically effective amount" refers to an amount of a compound sufficient to result in a therapeutic response. In the context of the present disclosure, the term "therapeutically effective amount" may also refer to an amount of an anti-VWF aptamer sufficient to result in a therapeutic response. A therapeutic response may be any response that a user (e.g., a clinician) would recognize as an effective response to treatment. The exact amount required will vary from subject to subject, depending on the subject's species, age, and general condition, the particular therapeutic agent, its mode and / or route of administration, etc. It will be understood, however, that the total daily usage amount of the compounds and compositions of the present disclosure may be determined by the attending physician within the scope of sound medical judgment.

[0026] Preventing, Prevent, Prevention: As used herein, the terms "prevent," "preventing," and "prevention" and grammatical variations thereof are used interchangeably. These terms refer to a method of partially or completely delaying or eliminating the onset or recurrence of a disorder or condition and / or one or more of its attendant symptoms, or a method of preventing a subject from acquiring or re-acquiring a disorder or condition, or a method of reducing a subject's risk of acquiring or re-acquiring a disorder or condition or one or more of its attendant symptoms.

[0027] Treating, Treatment, Treat: As used herein, the terms "treating," "treatment," and "treat" and grammatical variations thereof refer to administering an effective amount of a pharmaceutical composition to a subject so as to achieve a beneficial or desired clinical result, such as reversing, curing, alleviating, ameliorating, reducing, diminishing at least one symptom of a disease, or reducing the extent of the disease, stabilizing the disease state (e.g., not worsening), delaying or slowing the progression of the disease, ameliorating or alleviating the disease state, and remission (partial or complete; and detectable or undetectable).

[0028] Subject: As used herein, the term "subject" is used interchangeably with the terms "individual" and "patient" and refers to a vertebrate, preferably a mammal, more preferably a human.

[0029] Injection: As used herein, the term "injection" or "injectable formulation" refers to a composition that can be drawn into a syringe and injected subcutaneously, intraperitoneally, or intramuscularly into a subject (e.g., a human).

[0030] Parenteral administration: As used herein, the term "parenteral administration" of a pharmaceutical preparation refers to administration to a subject by a route other than the topical or oral route (i.e., non-topical and parenteral routes). Examples of parenteral routes include subcutaneous, intramuscular, intravascular (including intraarterial or intravenous), intraperitoneal, intraorbital, retrobulbar, peribulbar, intranasal, intrapulmonary, intrathecal, intraventricular, intraspinal, intracisternal, intraarticular, intrasternal, or intralesional administration. Parenteral administration can be, for example, by bolus injection or continuous infusion, either constant or intermittent and / or pulsatile, and can be via a needle or via a catheter or other tube.

[0031] Subcutaneous administration: As used herein, the term "subcutaneous administration" refers to common routes of administration of pharmaceutical compositions, including, but not limited to, subcutaneous injection and infusion. Infusion may be continuous or intermittent using an infusion pump or any other commercially available device.

[0032] Hemostatic and coagulation components Blood coagulation is a complex and dynamic biological process involving the continuous interaction of coagulation components, including the coagulation factors: factor II (FII), factor V (FV), factor VII (FVII), factor VIII (FVIII), factor IX (FIX), factor X (FX), factor XI (FXI), factor XII (FXII), and the cofactor, von Willebrand factor (VWF).

[0033] Factor VIII (FVIII), a large plasma glycoprotein (also known as antihemophilic factor A), is a critical component of the fluid-phase blood coagulation cascade. FVIII is primarily produced by hepatocytes and vascular endothelial cells. Human FVIII is one of the largest coagulation factors, containing three A-domains, a single B-domain, and two C-domains. It is activated via proteolytic cleavage by FXa and thrombin to generate activated FVIII heterotrimer (FVIIIa). FVIIIa acts as a nonenzymatic cofactor for the prothrombinase and tenase complex in the coagulation cascade, which accelerates FX activation in the presence of FIXa, phospholipids, and calcium ions (Fay et al., Blood Reviews, 2004, 18: 1-15). The half-life of FVIII is approximately 12 hours. To avoid excessive coagulation, FVIIIa must be inactivated by protein C (APC)-mediated cleavage shortly after activation. Inactivation of FVIIIa is a rapid process, which explains the short half-life of FVIIIa in the blood. As used herein, the terms "factor VIII(a)" and "FVIII(a)" include both FVIII and FVIIIa. Similarly, the terms "factor VIII" and "FVIII" may include both FVIII and FVIIIa.

[0034] FVIII present in plasma associates with von Willebrand factor (VWF) to form a noncovalent FVIII-VWF complex. VWF is a large, multimeric glycoprotein that plays an important role in hemostasis and thrombus formation. The human VWF preproprotein (GeneBank Reference No. NP_000543.2, SEQ ID NO: 1) (encoded by the cDNA: GeneBank Reference No. NM_000552.3, SEQ ID NO: 2) is processed to a mature polypeptide with multiple subdomains with distinct functions (Hassan and Saxena, Blood Coagul. Fibrinolysis, 2012, 23(1):11-22). VWF is a carrier protein for FVIII, binding FVIII to platelet surface glycoproteins and localizing FVIII to the site of platelet plug and subsequent clot formation. VWF also acts as a stabilizer of FVIII in the circulation by forming a noncovalent VWF-FVIII complex that protects FVIII from degradation by activated protein C (APC), thereby preventing premature proteolysis of FVIII (Koppelman et al., Blood. 1996; 87:2292-2300). Furthermore, VWF blocks the interaction of FVIII with lipoprotein-associated receptors, thereby increasing the half-life of FVIII in the circulation.

[0035] Furthermore, the interaction between VWF and FVIII plays an important role in the function, immunogenicity, and clearance of FVIII, and VWF essentially functions as a chaperone for FVIII. VWF plays an important protective role for FVIII both under normal physiological conditions and in hemophilia patients. In hemophilia patients who have developed FVIII inhibitors (e.g., antibodies against FVIII replacement) after treatment with FVIII replacement therapy, VWF can protect exogenous FVIII from binding to inhibitory antibodies (Gensana et al., Hemophilia. 2001; 7:369-374).

[0036] Plasma levels of VWF can affect the risk of bleeding (lower VWF levels) or thrombosis (higher VWF levels). A quantitative deficiency (low levels) of plasma VWF (e.g., <50%) is associated with an increased risk of bleeding, while high plasma levels of VWF (e.g., >150%) are associated with an increased risk of thrombosis (e.g., a higher risk of venous thromboembolism, ischemic stroke, coronary artery disease, myocardial infarction, and peripheral vascular disease).

[0037] Bleeding and bleeding disorders Defects in the clotting process can increase the risk of bleeding. For example, deficiencies in clotting factors and defects in platelet number or function cause bleeding disorders. Bleeding can occur inside the body (internal bleeding), under the skin, or on the surface of the skin (external bleeding).

[0038] As used herein, the term "bleeding disorders" refers to a heterogeneous group of conditions that occur when blood cannot clot properly. In normal clotting, platelets adhere together and form a plug at the site of an injured blood vessel. Clotting factors in the blood interact to form a fibrin clot (essentially a gel-like plug), which holds the platelets in place and prevents blood from escaping the blood vessel while allowing healing at the injury site. The inability to form a clot can be very dangerous and result in excessive bleeding. Bleeding can result from either too few or abnormal platelets, abnormal or low amounts of clotting factors, dysfunctional clotting factors (e.g., mutations in the genes encoding clotting factors), or abnormalities in the blood vessels. The severity of bleeding can be assessed according to guidelines such as the assessment tool reviewed by Rodeghiero et al., ISTH / SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. Sep 2010;8(9):2063-5. doi:10.1111 / j.1538-7836.2010.03975.x). Individuals with bleeding disorders may have both internal and external bleeding. Common symptoms of bleeding disorders include, but are not limited to, prolonged bleeding after injury, surgery, trauma, or menstruation; excessive bruising; bleeding into joints, muscles, and soft tissues; gastrointestinal bleeding; and spontaneous bleeding without a known or identifiable cause.

[0039] Bleeding disorders can be inherited or acquired. As used herein, the term "inherited bleeding disorders" (also called "congenital bleeding disorders") refers to a group of rare disorders caused by genetic deficiencies of clotting components. The most common bleeding disorders include hemophilia (e.g., hemophilia A and B) and VWD (e.g., types 1, 2, and 3). Hemophilia A or B is a rare inherited bleeding disorder that can range from mild to moderate to severe, depending on the level of residual factor activity present in the patient's plasma. The incidence of hemophilia A is approximately 1 in 5,000 male births, and the incidence of hemophilia B is approximately 1 in 25,000 male births. Collectively, they are among the most common inherited bleeding disorders worldwide. Von Willebrand disease (VWD) is the most common inherited bleeding disorder in the United States, affecting up to 1% of the U.S. population.

[0040] Bleeding can also result from a low number of platelets (thrombocytes) in the blood, a condition called thrombocytopenia. A normal platelet count in adults ranges from 150,000 to 450,000 platelets per microliter of blood. A platelet count below 150,000 platelets per microliter is considered lower than normal (thrombocytopenia). The risk of serious bleeding does not occur until the platelet count is very low, below 10,000 or 20,000 platelets per microliter. Mild bleeding can occur when the platelet count is below 50,000 platelets per microliter. A risk of serious bleeding can occur when the platelet count is very low, below 10,000 or 20,000 platelets per microliter. In rare cases, very low platelet counts can cause dangerous internal bleeding. Thrombocytopenia can occur in a variety of conditions, including inherited bleeding disorders and acquired conditions (e.g., side effects from medications). A low platelet count (thrombocytopenia) can occur due to insufficient platelets being made by the bone marrow, a defect in maintaining sufficient platelets in the blood, and / or an abnormality in the spleen that causes excess platelets to be retained.

[0041] Conditions that cause low platelet counts (thrombocytopenia) include, for example, thrombotic thrombocytopenic purpura (TTP), disseminated intravascular coagulation (DIC), immune thrombocytopenia (ITP), autoimmune diseases, enlarged spleen conditions (caused by cancer, severe liver disease, and bone marrow deficiency), viral or bacterial infections, and adverse reactions to drugs.

[0042] hemophilia A Classical hemophilia or hemophilia A (also known as factor FVIII deficiency) is an inherited bleeding disorder caused by X-chromosome-linked FVIII deficiency and affects almost exclusively males. Mutations in the gene encoding FVIII (i.e., the F8 gene) result in hemophilia A. This genetic mutation can result in absent or reduced synthesis of FVIII, or abnormal protein synthesis (Hong et al., Thrombosis Res., 2007, 119:1-13). The X-chromosome defect is inherited by female carriers who are not themselves hemophiliacs. Due to random chromosome activation, some female carriers can range from asymptomatic to symptomatic, depending on how much of their FVIII is inactivated.

[0043] Because blood cannot clot properly without sufficient FVIII, a clinical sign of hemophilia A is an increased tendency to bleed; for example, a small cut or injury carries the risk of excessive bleeding. Furthermore, hemophilia patients may suffer from internal bleeding, which can damage joints (including the knees, ankles, elbows, and hips), muscles, organs, and tissues (e.g., the soft tissues beneath the skin) over time. The severity of hemophilia bleeding depends on the level of FVIII deficiency. Hemophilia A can be mild, moderate, or severe in individual patients (Table 1), determined based on the plasma FVIII deficiency (IU) (Bolton-Maggs and Pasi, Lancet, 2003, 361: 1801-1809).

[0044] [Table 1]

[0045] With mild inherited bleeding disorders, bleeding symptoms occur in otherwise healthy individuals. Patients with mild bleeding disorders may not frequently suffer from bleeding in daily life, but may experience problems following hemostatic challenges, including, but not limited to, trauma, tooth extraction, and surgery.

[0046] Treatment for hemophilia A primarily focuses on increasing the blood activity of deficient clotting factor VIII through factor replacement to control and / or prevent active bleeding in patients. Currently available treatments include human plasma-derived lyophilized FVIII concentrates and recombinant clotting factors produced by genetically engineered cells. FVIII concentrates have a short half-life in plasma, averaging approximately 12 hours in adults, ranging from 6 to 29 hours in individual hemophilia A patients, and even shorter in younger children. FVIII replacement therapy for hemophilia often requires frequent intravenous injections of the therapeutic agent.

[0047] Patients with severe hemophilia A require increased doses and longer dosing intervals for prophylactic treatment. Several technologies are under development to extend the half-life of FVIII in blood. Because most plasma FVIII circulates in a high-affinity complex with VWF, most FVIII is removed while not bound to VWF. This is supported by studies showing that FVIII in hemophilia patients is significantly affected by plasma VWF levels. For example, Valentino showed that patients with high VWF levels had significantly longer FVIII half-lives (Valentino et al., Haemophilia, 2014, 20: 607-615). Targeting VWF chaperones to increase plasma FVIII-VWF complex levels may provide an alternative strategy to extend the half-life of FVIII in plasma.

[0048] According to the present disclosure, the VWF targeting agent can bind to VWF and extend the half-life of VWF, thereby extending the half-life of FVIII. von Willebrand disease (VWD) Although deficiencies of factor VIII (hemophilia A) and factor IX (hemophilia B) are well recognized, von Willebrand disease (VWD) is much more common. VWF deficiency (e.g., quantitative reduction, functional deficiency, or complete absence) leads to different types of VWD. VWD can affect both men and women. Conversely, abnormally elevated VWF concentration or function can also cause serious medical disorders such as venous thromboembolism (VTE). VWD is classified into three distinct types (types 1, 2, and 3) based on the levels of VWF and FVIII activity in the blood.

[0049] Type 3 VWD is the most severe and least common form, involving a complete deficiency of VWF. Patients with type 3 VWD have little or no VWF in their blood. The amount of FVIII in the blood also drops to low levels, without VWF to act as a carrier. Patients with type 3 VWD have problems forming both platelet plugs and fibrin clots. Patients with type 3 VWD experience spontaneous bleeding into joints and muscles, and frequent bleeding from the nose and mouth. Women with type 3 VWD may experience prolonged and very heavy menstrual bleeding.

[0050] Type 2 VWD is associated with a qualitative defect in VWF and can be as severe as type 3 VWD in some patients. It includes four subtypes: types 2a, 2b, 2m, and 2n. Type 2a is caused by a defect in VWF multimerization due to an incorrect size of the VWF protein. Abnormal VWF multimers prevent platelets from forming a good platelet plug. In type 2b, the VWF protein is abnormally active and exhibits a variant of spontaneous platelet binding. VWF adhesion causes the body to rapidly remove platelets, resulting in a shortage of both platelets and VWF in the blood. Type 2m is caused by a defect in VWF ligand binding to intact multimers. In type 2n, VWF is defective in FVIII binding and fails to act as a carrier and protector of FVIII. Blood levels of FVIII are low because there is insufficient VWF to prevent it from being degraded. Patients with type 2n VWD may appear to have mild hemophilia with some of the same symptoms. In particular, type 2b VWD is caused by mutations in the A1 domain of VWF, which cause constitutive activation of the A1 domain binding to the GPIb receptor on platelets, resulting in depletion of VWF, FVIII, and platelets.

[0051] Type 1 VWD is the mildest and most common form, accounting for up to 85% of pf VWD cases (reviewed by Robertson et al., Pediatr Clin North Am., 2008, 55(2): 377-392), and is associated with quantitative loss of VWF but qualitatively normal VWF. Lower levels of FVIII may be seen in type 1 VWD due to insufficient VWF in the blood. A minority of type 1 VWD patients may experience severe bleeding. Type 1 VWD is a highly heterogeneous group of genetic defects, representing a total of 85 unique SNPs, with only partial deficiency of VWF. For example, the Vicenza variant of type 1 VWD is characterized by low plasma VWF levels and ultranormal VWF multimers, caused by an increased rate of VWF clearance (Alessandra et al., Blood 2002, 99(1): 180-184).

[0052] Other rare bleeding disorders Deficiencies in other clotting factors can cause rare bleeding disorders, for example, rare factor deficiencies, including deficiencies of Factor I, II, V, VII, X, XI, XII, and XIII. In additional genetic disorders, other bleeding disorders may be acquired, such as, for example, platelet disorders, which are the most common cause of acquired bleeding disorders.

[0053] Currently, standard treatment for hemophilia A and VWD involves frequent intravenous infusions of FVIII and VWF preparations or concentrates, including complexes of FVIII and VWF derived from human donor plasma, recombinant FVIII preparations, or recombinant VWF preparations. In patients with severe hemophilia A, FVIII injections are used for prophylactic treatment. Because FVIII has a short plasma half-life, patients must receive intravenous administration approximately three times per week. VWD can be treated by replacement therapy using concentrates containing VWF of plasma or recombinant origin. One approach to increasing the functional half-life of VWF is through PEGylation of VWF, which indirectly enhances the half-life of FVIII present in plasma (WO 2006 / 071801, the contents of which are incorporated by reference in their entirety). PEGylation of VWF antigen at specific sites can protect VWF from macrophage-mediated clearance in plasma (Fazavaza et al., J. Thromb. Haemost., 2020; 18:1278-1290, the contents of which are incorporated herein by reference in their entirety).

[0054] It is highly desirable to create new treatments that can extend the functional half-life of FVIII and VWF in patients with bleeding disorders (e.g., hemophilia and VWD), while allowing the drugs to be administered less frequently or by other less cumbersome and less painful administration means.

[0055] The inventors of the present disclosure have surprisingly found that a VWF-targeting aptamer modified with PEG conjugation can increase VWF and FVIII levels in the blood after a single-dose treatment. The VWF-targeting nucleic acid does not interfere with the function of FVIII in plasma at any concentration, and does not interfere with the function of VWF in plasma at relatively low concentrations.

[0056] According to the present disclosure, a VWF targeting agent is provided that binds to VWF in plasma, blocks its clearance, and thereby extends the half-life of the VWF-FVIIII complex in plasma. The VWF targeting agent can be used to treat inherited bleeding disorders, particularly hemophilia A and VWD (e.g., type 1, Vicenza subtype, type 2 (including subtypes 2a, 2b, 2m, and 2n), and type 3).

[0057] VWF targeting agent As used herein, the term "targeting agent" refers to an agent that specifically binds to and interacts with a molecule of interest. A VWF targeting agent is an agent that binds to VWF directly or indirectly via another agent to regulate VWF biological activity (also referred to as a "VWF binding agent"), such as the interaction between VWF and FVIII and the half-life of the VWF and FVIII-VWF complex. Generally, the targeting agent may be an antibody, nanobody, peptide, oligonucleotide, RNA (e.g., siRNA, microRNA), synthetic polynucleotide (e.g., aptamer), or small molecule capable of binding to VWF. VWF targeting agents also include agents that bind to VWF and thereby block its clearance mechanism. In some embodiments, VWF targeting agents can be used to treat bleeding disorders, particularly hemophilia A and VWD. VWF targeting agents can also be used to block VWF clearance in the blood.

[0058] In some embodiments, the VWF targeting agent may be a nucleic acid-based agent, particularly an aptamer that binds to VWF, and variants thereof. In some examples, the VWF-binding agent is an aptamer or a salt thereof. Aptamers are short (i.e., typically 12 to 80 nucleotides in length) single-stranded nucleic acid polymers that bind to VWF with high affinity and specificity. Aptamers are synthetic polynucleotides that can be isolated using the SELEX process.

[0059] Aptamers Aptamers are biomolecules that bind to specific target molecules and modulate the activity, structure, or function of the target. Aptamers are often referred to as "chemical antibodies" because they have characteristics similar to antibodies. Aptamers can be either nucleic acid- or amino acid-based, i.e., nucleic acid aptamers or peptide aptamers. Nucleic acid aptamers have specific binding affinity for target molecules through interactions other than classical Watson-Crick base pairing. Nucleic acid aptamers can specifically bind to a selected target and, through binding, block the target's functional ability. The aptamers of the present disclosure are synthetic oligonucleotides. Typical nucleic acid aptamers are approximately 10-15 kDa in size, bind their targets with subnanomolar affinity, and discriminate between closely related targets. Targets of nucleic acid aptamers can be, but are not limited to, proteins, nucleic acid molecules, peptides, small molecules, and whole cells.

[0060] Nucleic acid aptamers may be ribonucleic acid (RNA), deoxyribonucleic acid (DNA), or a mixture of ribonucleic acid and deoxyribonucleic acid (DNA / RNA hybrid). Aptamers may be single-stranded. Suitable nucleotide lengths for aptamers range from about 15 to about 150 nucleotides (nt), and in various other preferred embodiments, are 15-30 nt, 20-25 nt, 20-45 nt, 30-100 nt, 30-60 nt, 25-70 nt, 25-60 nt, 40-60 nt, 25-40 nt, 30-40 nt, 15 nt, 16 nt, 17 nt, 18 nt, 19 nt, 20 nt, 21 nt, 22 nt, 24 nt, 26 nt, 28 nt, 29 nt, 30 nt, 31 nt, 32 nt, 33 nt, 34 nt, 35 nt, 36 nt, 37 nt, 38 nt, 39 nt, 40 nt, 41 nt, 42 nt, 43 nt, 44 nt, 45 nt, 46 nt, 47 nt, 48 nt, 49 nt, 50 nt, 51 nt, 52 nt, 53 nt, 54 nt, 55 nt, 56 nt, 57 nt, 58 nt, 59 nt, 60 nt, 61 nt, 62 nt, 63 nt, 64 nt, 65 nt, 66 nt, 67 nt, 68 nt, 69 nt, 70 The aptamer may be any number of 3 nt, 24 nt, 25 nt, 26 nt, 27 nt, 28 nt, 29 nt, 30 nt, 31 nt, 32 nt, 33 nt, 34 nt, 35 nt, 36 nt, 37 nt, 38 nt, 39 nt, 40 nt, 41 nt, 42 nt, 43 nt, 44 nt, 45 nt, 46 nt, 47 nt, 48 nt, 49 nt, or 50 nt, or a length of 30-50 nt, 40-70 nt, or 50-100 nt. However, the sequence may be designed with sufficient flexibility to accommodate the interaction of the aptamer with the target.

[0061] As used herein, the terms "nucleic acid," "polynucleotide," and "oligonucleotide" are used interchangeably. A nucleic acid molecule is a polymer of nucleotides consisting of at least two nucleotides covalently linked to each other. Nucleic acid molecules include DNA (deoxyribonucleotides), RNA (ribonucleotides), and recombinant RNA and DNA molecules, or analogs of DNA or RNA produced using nucleotide analogs. Nucleic acids may be single-stranded or double-stranded, linear, or circular. The term also includes fragments of nucleic acids, such as naturally occurring RNA or DNA that can be recovered using the disclosed extraction methods, or artificial DNA or RNA molecules artificially synthesized in vitro (i.e., synthetic polynucleotides). The molecular weight of the nucleic acid is also not limited and may range from a few base pairs (bp) to several hundred base pairs, for example, from about 2 nucleotides to about 1,000 nucleotides, or from about 10 nucleotides to 5,000 nucleotides, or from about 10 nucleotides to about 1,000 nucleotides.

[0062] The term "nucleotide (nt)" refers to a monomer of nucleic acid, a chemical compound consisting of a heterocyclic base, a sugar, and one or more phosphate groups. The bases are derivatives of purines and pyrimidines, and the sugars are pentoses (either deoxyribose or ribose).

[0063] As used herein, the term "modification" refers to a technique for chemically reacting a nucleic acid, such as an oligonucleotide, with a chemical agent. Nucleic acids may be modified at the base moiety, sugar moiety, or phosphate backbone. Modifications include, but are not limited to, sugar modifications at the 2' position, pyrimidine modifications at the 5' position, purine modifications at the 8' position, modifications at the exocyclic amine, 4-thiouridine substitution, 5-bromo- or 5-iodo-uracil substitution, backbone modifications, phosphorothioate or alkylphosphate modifications, methylation, and unusual base pair combinations such as the isobases isocytidine and isoguanidine. Modifications may also include 3' and 5' modifications, such as capping. Nucleic acid molecules may also be modified by conjugation to moieties with desired biological properties. Such moieties may include, but are not limited to, chemical compounds, peptides and proteins, carbohydrates, antibodies, enzymes, polymers, drugs, and fluorophores. In some examples, polynucleotides are conjugated to lipophilic compounds such as cholesterol, dialkylglycerol, diacylglycerol, or non-immunogenic high molecular weight compounds or polymers such as PEG (polyethylene glycol), or other water-soluble pharmaceutically acceptable polymers, including, but not limited to, polysaccharides such as polyaminoamines (PAMAM) and dextran, or polyoxazolines (POZ). Modifications may be intended, for example, to increase the in vivo stability of the nucleic acid molecule or to enhance or mediate delivery of the molecule.

[0064] Aptamers can be monovalent or multivalent. Aptamers can be monomers, dimers, trimers, tetramers, or other higher-order multimers. Individual aptamer monomers can be linked to form multimeric aptamer fusion molecules. As a non-limiting example, a linking oligonucleotide (i.e., a linker) can be designed to contain sequences complementary to both the 5'-arm and 3'-arm regions of a random aptamer to form a dimeric aptamer. For trimeric or tetrameric aptamers, small trimeric or tetrameric (i.e., Holliday junction-like) DNA nanostructures can be engineered to contain sequences complementary to the 3'-arm regions of a random aptamer, thereby generating multimeric aptamer fusions through hybridization. Additionally, 3-5 or 5-10 dT-rich nucleotides can be engineered into a linker polynucleotide as a single-stranded region between aptamer-binding motifs, providing flexibility and freedom for multiple aptamers to coordinate and synergize multivalent interactions with cellular ligands or receptors. Alternatively, multimeric aptamers can be formed by mixing biotinylated aptamers with streptavidin.

[0065] As used herein, the term "multimeric aptamer" or "multivalent aptamer" refers to an aptamer containing multiple monomer units, each of which can be an aptamer in its own right. Multivalent aptamers have multivalent binding properties. Multimeric aptamers can be homomultimers or heteromultimers. The term "homomultimer" refers to a multimeric aptamer containing multiple binding units of the same type, i.e., each unit binds to the same binding site on the same target molecule. The term "heteromultimer" refers to a multimeric aptamer containing multiple binding units of different types, i.e., each binding unit binds to a different binding site on the same target molecule, or each binding unit binds to a binding site on a different target molecule. Thus, a heteromultimer can refer to a multimeric aptamer that binds to one target molecule at different binding sites, or to a multimeric aptamer that binds to different target molecules. A heteromultimer that binds to different target molecules can also be called a multispecific multimer.

[0066] Aptamers can be generated against target molecules (e.g., VWF) using a process known as in vitro selection (Ellington and Szostak, Nature, 1990; 346: 818-822) or SELEX (Tuerk and Gold, Science, 1990, 249: 505-510). This method allows for the in vitro evolution of nucleic acid molecules that bind highly specifically to target molecules. The SELEX method is described, for example, in U.S. Patent No. 7,087,735, U.S. Patent No. 5,475,096, and U.S. Patent No. 5,270,163, the contents of each of which are incorporated herein by reference in their entirety. Nucleic acid aptamers can be synthesized using methods well known in the art. For example, the disclosed aptamers can be synthesized using standard oligonucleotide synthesis techniques known in the art.

[0067] VWF aptamer According to the present disclosure, the VWF targeting agent is a polynucleotide, its salt, or its derivative, which targets VWF, for example, to regulate the interaction between VWF and FVIII in plasma. In some embodiments, the VWF targeting agent is an aptamer that specifically binds to VWF. Therefore, the anti-VWF aptamer is also called a "VWF binding agent."

[0068] When synthetic polynucleotides bind to VWF, they can block the clearance mechanism in the blood, thereby increasing the level of VWF antigen in the blood. Because the FVIII-VWF complex is protected from proteolysis, blockage can increase the level of factor VIII in the blood.

[0069] In some embodiments, the synthetic polynucleotide that binds to VWF may be 15 to 50 nucleotides in length, or 20 to 30 nucleotides in length (e.g., 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, and 30 nucleotides in length). The synthetic polynucleotide may further comprise a double-stranded region. The double-stranded region may be about 6 to about 9 nucleotides in length. The double-stranded region may be formed by 6, 7, 8, or 9 nucleotides. Additionally, the double-stranded region may be formed by 6 or more 3' and 5' nucleotides at or near the end of the sequence.

[0070] In some embodiments, synthetic polynucleotides may be chemically modified. Each nucleotide may contain at least one chemical modification. Such chemical modifications may be present in the sugar, nucleobase, or internucleoside linker of the synthetic polynucleotide. Modifications to the sugar may include, but are not limited to, 2'-amino, 2'-O-alkyl, 2'-fluoro, and 2'-O-methyl modifications. As a non-limiting example, a synthetic polynucleotide targeting VWF contains a 2'-O-methyl modification. In some embodiments, terminal cap structures may be incorporated at the 3' and / or 5' ends of the synthetic polynucleotide. Cap structures include a 5'-5' inverted nucleotide cap at the 5' end of the synthetic polynucleotide and a 3'-3' inverted nucleotide cap at the 3' end of the synthetic polynucleotide. The cap structure may be an inverted deoxythymidine or an amino group (NH).

[0071] Synthetic polynucleotides may be further modified to include one or more conjugates, such as PEG (polyethylene glycol) moieties, at the 5' or 3' end of the synthetic polynucleotide. The PEG moiety may be of any size or branched configuration. PEG sizes can range from about 5 kD to about 200 kD. PEG may be linear or branched, with multiple PEG chains attached together. Short 3'- and 5'-PEG conjugates do not interfere with binding specificity or affect the target affinity of the synthetic polynucleotide.

[0072] In one embodiment, the VWF-binding agent is a synthetic polynucleotide comprising at least 21 contiguous nucleotides of SEQ ID NO: 3 (5'GCCAGGGACCUAAGACACAUGUCCCUGGC-3'), which sequence is derived from an aptamer that specifically binds to VWF. In one embodiment, the VWF-binding agent may be a synthetic polynucleotide comprising at least 21 contiguous nucleotides of SEQ ID NO: 3. Furthermore, the synthetic polynucleotide may exhibit a double-stranded region having at least 6 nucleotides, or at least 7 nucleotides, or at least 8 nucleotides, or at least 9 nucleotides. In one embodiment, the double-stranded region of 6 or more nucleotides is at or near (e.g., within 1 to 10 nucleotides of) a terminus of the synthetic polynucleotide.

[0073] In some embodiments, the synthetic polynucleotide comprises an inverted deoxythymidine at the 3' end of the sequence. As a non-limiting example, a VWF targeting agent is a synthetic polynucleotide comprising the structure: mGmCmCmAmGmGmGmAmCmCmUmAmAmGmAmCmAmCmAmUmGmUmCmCmCmUmGmGmC-idT (SEQ ID NO: 4) (BT99), where "NH" is a 5'-hexylamine linker phosphoramidite, "idT" is an inverted deoxythymidine, and "mN" is a 2'-O-methyl-containing residue.

[0074] In some embodiments, the synthetic polynucleotide comprises an inverted deoxythymidine at the 3' end of the sequence and an amino group (NH2) at the 5' end of the sequence. As a non-limiting example, a VWF targeting agent is a synthetic polynucleotide comprising the structure: NH2-mGmCmCmAmGmGmGmAmCmCmUmAmAmGmAmCmAmCmAmUmGmUmCmCmCmUmGmGmC-idT (SEQ ID NO: 5) (BT100), where "NH" is a 5'-hexylamine linker phosphoramidite, "idT" is an inverted deoxythymidine, and "mN" is a 2'-O-methyl-containing residue.

[0075] In some embodiments, the synthetic polynucleotide that binds to VWF further comprises a PEG moiety conjugated to the 5' end of the sequence. As a non-limiting example, the VWF targeting agent is a synthetic polynucleotide comprising the structure: PEG40K-NH-mGmCmCmAmGmGmGmAmCmCmUmAmAmGmAmCmAmCmAmUmGmUmCmCmCmUmGmGmC-idT (SEQ ID NO: 6) (BT200), where "NH" is a 5'-hexylamine linker phosphoramidite, "idT" is an inverted deoxythymidine, "mN" is a 2'-O-methyl-containing residue, "PEG" is polyethylene glycol, and PEG40K is a PEGylated moiety having a molecular weight of approximately 40 KDa.

[0076] PEGylated BT200 specifically binds to the A1 domain of VWF in plasma and interferes with its regulation and functionality (Zhu et al., J Thromb Haemost. 2020 May;18(5):1113-1123, the contents of which are incorporated herein by reference in their entirety). One mechanism is that BT200 binding to VWF can protect nucleic acid-protein complexes from clearance by inhibiting the interaction of VWF with macrophage low-density lipoprotein receptor-related protein-1 (LRP1) (Fazavana et al., J Thromb Haemost., 2020, 1278-1290). In this regard, BT200 can be used as an antihemorrhagic agent. The inventors of the present disclosure have found that at low doses, BT200 blocks the clearance of VWF antigen from the circulation, resulting in a sustained increase in the concentrations of both VWF antigen (VWF Ag) and FVIII, but has negligible effect on the activity of either. At higher doses, BT200 blocks the clearance of VWF and inhibits VWF activity, but not FVIII activity. Thus, BT200 can be used to correct VWF and / or FVIII deficiencies in patients with inherited bleeding disorders (e.g., VWD type 1, VWD type 2b, and VWD type 3).

[0077] Subcutaneously injected BT200 exhibits a prolonged half-life lasting 7-12 days in the circulation, providing good subcutaneous bioavailability (Zhu et al., J Thromb Haemost, 2020, 1113-1123).

[0078] In other embodiments, the VWF-binding agent has the sequence: PEG40K-NH-mGmGmGmAmCmCmUmAmAmGmAmCmAmCmAmUmGmUmCmCmC-idT (ARC15105) (SEQ ID NO: 7), or the sequence: PEG20K-NH-mGmCmGmUdGdCdAmGmUmGmCmCmUmUmCmGmGmCdCmGsdTmGdCdGdGdTmGmCdCmUdCdCmGmUdCmAmCmGmCidT (ARC1779) ( 8), where "NH" is a 5'-hexylamine linker phosphoramidite, "idT" is an inverted deoxythymidine, "mN" is a 2'-O-methyl-containing residue, "dN" is a deoxynucleotide residue, "sdT" is a phosphorothioate deoxythymidine residue, "PEG" is polyethylene glycol, and PEG20K is a PEGylated moiety having a molecular weight of approximately 20 KDa.

[0079] In some embodiments, the VWF-binding agent may comprise a synthetic polynucleotide having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO:3.

[0080] [Table 2]

[0081] Pharmaceutical Composition In another aspect of the present disclosure, pharmaceutical compositions and formulations are provided that include any one of the anti-VWF aptamers of the present disclosure. The VWF-binding agent is formulated into a formulation suitable for administration to a subject in need thereof. Suitable formulations for pharmaceutical compositions of the present disclosure, particularly nucleic acid-based compositions, are taught in International Publication No. 2013 / 090648 (International Application No. PCT / US2012 / 069610), the contents of which are incorporated herein by reference in their entirety. Methods for making formulations are well known in the art and are described, for example, in Remington: The Science and Practice of Pharmacy (20th ed., ed. AR Gennaro AR.), Lippincott Williams & Wilkins, 2000, the contents of which are incorporated herein by reference in their entirety.

[0082] The pharmaceutical compositions of the present disclosure may include at least one VWF targeting agent, such as BT200, as an active ingredient. The composition further comprises at least one pharmaceutically acceptable carrier, diluent, or excipient, such as saline or distilled water. Optionally, the composition may comprise an excipient that stabilizes the aptamer agent, thereby maintaining the therapeutic activity of the agent. In some embodiments, the composition may comprise an excipient, such as a salt, sugar, or alcohol, that facilitates diffusion of the aptamer agent.

[0083] By way of non-limiting example, excipients may include sugars such as sucrose, trehalose, fructose, galactose, mannitol, dextran, and glucose; polyalcohols such as glycerol and sorbitol; proteins such as albumin; hydrophobic molecules such as oils; hydrophilic polymers such as polyethylene glycol; isomers such as diastereomers and enantiomers; mixtures of isomers including racemic mixtures, salts, solvates, and polymorphs thereof.

[0084] In some embodiments, the composition may be in the form of a liquid solution or suspension. In some cases, the composition is sterile for injection. In some embodiments, the VWF targeting agent of the present disclosure is formulated for oral administration. The formulation may be in the form of a tablet or capsule. In some embodiments, the VWF agent of the present disclosure is formulated for intranasal administration. The intranasal formulation may be in the form of a powder, nasal spray, or aerosol. In some embodiments, the VWF agent of the present disclosure is formulated for parenteral administration. The formulation contains only pharmaceutically acceptable excipients, diluents, carriers, and adjuvants that are safe for parenteral administration to humans at concentrations used under the same or similar standards as excipients, diluents, carriers, and adjuvants deemed safe by the Federal Drug Administration or other foreign authorities. The pharmaceutical formulation may be in the form of a ready-to-use solution, concentrate, or lyophilized preparation that can be reconstituted with the indicated amount of a diluent suitable for parenteral injection, such as water, saline, or buffer. In some examples, the formulation is a stable aqueous pharmaceutical formulation that remains within its physical, chemical, microbiological, therapeutic, and toxicological specifications throughout its shelf life. In some embodiments, the VWF targeting agents of the present disclosure are formulated for inhalation.

[0085] In some embodiments, the VWF targeting agent of the present disclosure may be formulated for controlled release of the active agent. As a non-limiting example, the formulation for controlled release may include a biocompatible polymer. The choice of polymer depends on the rate of drug release required for a particular treatment regimen. Biocompatible polymers suitable for sustained release include, but are not limited to, biodegradable polymers such as polyamides, such as poly(amino acids) and poly(peptides), polyesters, such as poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid), and poly(caprolactone), poly(anhydrides), polyorthoesters, polycarbonates, and their chemical derivatives, copolymers, and mixtures thereof. Biocompatible polymers may include non-degradable polymers such as polysaccharides, polyethers (e.g., poly(ethylene oxide), poly(ethylene glycol), and poly(tetramethylene oxide)), vinyl polymers (e.g., polyacrylates, acrylic acid, poly(vinyl alcohol), poly(vinylpyrrolidone), and poly(vinyl acetate)), polyurethanes, cellulosic polymers (e.g., cellulose, alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitrocellulose, and cellulose acetate), polysiloxanes, and other silicone derivatives. The sustained release of the drug may last for more than two months, one month, three weeks, two weeks, one week, six days, five days, four days, three days, two days, or one day. The amount of drug in a composition for sustained release may comprise about 0.1% to about 30%, or about 0.1% to about 10%, or about 1% to about 10%, or about 0.5% to about 5% (w / w) of the formulation, for example, about 0.1% (w / w), about 0.2% (w / w), about 0.5% (w / w), about 1.0% (w / w), about 2.0% (w / w), about 5.0% (w / w), about 10% (w / w), about 12% (w / w), about 15% (w / w), about 20% (w / w), about 25% (w / w), or about 30% (w / w) of the formulation.

[0086] In some embodiments, the VWF targeting agent is formulated as an injectable thermosensitive gel formulation. As used herein, the term "thermosensitive gel formulation" refers to a formulation that exists as a mobile viscous liquid at low temperatures but forms a firm, semi-solid gel at higher temperatures. Specifically, the formulation is liquid at room temperature or lower, but once injected, the gel creates a drug depot at the injection site. The formulation may contain a thermosensitive polymer. As used herein, the term "gel" refers to the semi-solid phase that spontaneously forms when the temperature of a thermosensitive polymer solution is raised above the gelation temperature of the polymer. Exemplary thermosensitive polymers may include PLGA-PEG-PLGA triblock copolymer, poloxamer, pluronic acid F127, and polyoxyethylene-polyoxypropylene (PEO-PPO) block copolymer. In some embodiments, the gelation temperature of the formulation is about 30°C to about 40°C.

[0087] In some embodiments, the VWF targeting agent may be encapsulated in a liposomal formulation. As used herein, the term "liposome" refers to a formulation consisting of at least one lipid bilayer membrane surrounding an aqueous interior compartment. Liposomes may be small unilamellar vesicles (SUVs) with a single membrane and typically ranging from 0.02 to 0.05 μm in diameter, large unilamellar vesicles (LUVs) typically greater than 0.05 μm, or large oligolamellar vesicles with multiple, usually concentric, membrane layers typically greater than 0.1 μm. Liposomes are formulated to carry a VWF agent contained within the aqueous interior space or distributed across the lipid bilayer.

[0088] In some embodiments, the VWF targeting agent may be formulated as an implantable solid formulation or coated onto the surface of an implant (eg, a stent). The concentration of the VWF targeting agent in the pharmaceutical formulation will vary depending on various factors, including the dose of the agent administered and the route of administration.

[0089] Treatment, Administration and Dosage In one aspect, the VWF targeting agents of the present disclosure may be used to treat bleeding disorders, more specifically to treat inherited bleeding disorders, such as hemophilia A (mild, moderate, and severe hemophilia), and VWD (types 1, 2b, and 3).

[0090] In some embodiments, the VWF targeting agent of the present disclosure may be used for the treatment and prophylactic treatment of bleeding disorders.As used herein, the term "prophylactic treatment" generally refers to preventive treatment to prevent bleeding by regular infusion of blood coagulation factor concentrates to patients with bleeding disorders.Patients with severe types of bleeding disorders (such as severe hemophilia and type 3 VWD) who receive prophylactic treatment may experience a reduced risk of bleeding and reduced joint damage.

[0091] In some embodiments, the VWF targeting agents of the present disclosure may be used in combination with clotting factor replacement therapy (also known as clotting factor replacement). For example, the VWF targeting agents may be used in combination with FVIII replacement therapy to treat hemophilia A, such as mild hemophilia, moderate hemophilia, and severe hemophilia, in patients. In a preferred embodiment, the patient has been diagnosed with severe hemophilia.

[0092] Regular treatment with FVIII prophylaxis can significantly protect patients with hemophilia A, especially those with severe hemophilia, from spontaneous bleeding episodes. Plasma-derived FVIII concentrates and recombinant FVIII preparations are currently available as treatments for hemophilia A. Because the short circulating half-life of FVIII in blood necessitates regular intravenous FVIII infusions to maintain therapeutic plasma FVIII levels, the administration schedule has a significant clinical impact on patient compliance. Recent efforts have focused on developing new approaches to extend the half-life of FVIII replacement, such as recombinant FVIII modification. However, clinical trials using modified recombinant FVIII molecules have shown a modest increase in half-life (approximately 1.5-fold) compared with wild-type recombinant FVIII (Pipe et al., Blood, 2016, 128: 2007-2016).

[0093] Recently, it has been reported that VWF peptides can effectively extend endogenous FVIII survival in VWF-deficient mice, and that extending the half-life of plasma VWF carrier fragments can significantly extend FVIII half-life in VWF-deficient mice (Yee et al., Blood, 2014, 124:445-452). Drugs that can increase VWF levels can be used to extend the half-life of FVIII in the blood, thereby increasing FVIII levels in patients with low FVIII activity (e.g., hemophilia and VWD). Research conducted by the inventors demonstrated that administration of the VWF-binding agent, BT200, can dose-dependently increase VWF and FVIII levels in the blood. BT200 binds to VWF and prevents VWF clearance in the blood. The increased VWF forms FVIII-VWF complexes, thereby increasing FVIII levels in the blood.

[0094] In some embodiments, the VWF targeting agent of the present disclosure may be used in combination with a recombinant FVIII preparation or a plasma-derived FVIII concentrate to extend the half-life of FVIII in the blood of hemophilia patients.The patient may have mild, moderate, or severe hemophilia.In particular, the patient has severe hemophilia.

[0095] In some embodiments, the VWF targeting agents of the present disclosure may be used in combination with VWF replacement therapy to treat VWD, particularly type 3 VWD, type 2 VWD, and type 1 VWD. In some examples, the VWF targeting agents may be used in combination with a VWF replacement preparation. The VWF replacement preparation may be a plasma-derived factor concentrate containing both FVIII and VWF (i.e., an FVIII / VWF concentrate) and a recombinant VWF preparation. As a non-limiting example, the recombinant VWF preparation may be Vonicog alfa, a rVWF produced in genetically modified CHO cells that express both VWF and FVIII (Turecek et al., Hamostaseologie, 2009, 29(Suppl.):S32-38).

[0096] In other examples, the VWF targeting agent may be used in combination with DDAVP therapy, which may stabilize and increase endogenous VWF and FVIII levels released upon stimulation with DDAVP.

[0097] In some embodiments, the VWF targeting agents of the present disclosure can be used to maintain appropriate VWF levels in the blood to protect FVIII from degradation. VWF can be endogenous, released by VWF-producing cells in vivo, or exogenous, injected for in vitro VWF replacement. FVIII can be endogenous or exogenous.

[0098] In some embodiments, VWF targeting agents can be used to increase platelet counts in patients with type 2b VWD, particularly in patients with type 2b VWD who have thrombocytopenia due to platelet aggregation. The VWF targeting agents, such as BT200, can increase the number of platelets in the blood.

[0099] This VWF targeting agent can increase the number of platelets in blood.Therefore, the VWF targeting agent can be used to treat thrombocytopenia, which is a condition in which the number of platelets in the patient's blood is low.Thrombocytopenia can occur in various conditions, such as bone marrow disorder, side effects of drugs, spleen enlargement associated with cancer and severe liver disease, autoimmune disease, conditions caused by exposure to toxic chemicals, and infection.

[0100] In particular, BT200 can maintain sustained elevation of VWF and FVIII levels in the blood. In some embodiments, the VWF targeting agents, compositions, and methods can be used to treat other rare deficiencies of coagulation components, such as rare inherited bleeding disorders (RBDs), including deficiencies of the clotting factors fibrinogen, FII, FV, a combination of FV and FVIII, FVII, FX, FXI, FXIII, and congenital deficiencies of vitamin K-dependent factors (VKCFDs).

[0101] According to the present disclosure, the method includes administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising at least one VWF targeting agent. In some examples, the targeting agent is a VWF-binding agent. The VWF-binding agent is an antibody, nanobody, peptide, oligonucleotide, RNA (e.g., siRNA, microRNA), synthetic polynucleotide (e.g., aptamer), or small molecule. In some embodiments, the VWF-binding agent is a synthetic polynucleotide selected from the group consisting of SEQ ID NO: 3, BT99 (SEQ ID NO: 4), BT100 (SEQ ID NO: 5), BT200 (SEQ ID NO: 6), ARC15105 (SEQ ID NO: 7), and ARC1779 (SEQ ID NO: 8), and variants thereof. In a preferred embodiment, the VWF-binding agent is BT200 (SEQ ID NO: 6).

[0102] The VWF targeting agent may increase the levels of FVIII and VWF in the blood of a subject being treated with the agent. The VWF targeting agent may also increase the platelet count in the subject. As a non-limiting example, a VWF targeting agent is BT200 (SEQ ID NO: 6).

[0103] According to the present disclosure, treatment regimens such as dose, dose-response relationship, loading dose and maintenance dose, as well as administration schedule (such as interval and timing), administration route, and formulation are considered and determined.

[0104] In some embodiments, VWF targeting agents may be administered to a subject in need thereof by any administration route. Agents and compositions may be formulated for parenteral or enteral administration, or other suitable routes. Parenteral administration may be performed by injection or by insertion of an indwelling catheter, including, but not limited to, intravenous (IV), intramuscular (IM), subcutaneous (SC), intradermal injection, epidural injection, intracerebral (intracerebral) administration, intraventricular (intraventricular) administration, extra-amniotic administration, intranasal administration, intraarterial, intracardiac, intraosseous infusion (IO), intraperitoneal infusion or injection, transdermal diffusion, enteral and gastrointestinal routes, topical administration, and oral routes.

[0105] As a non-limiting example, the VWF targeting agent is administered by subcutaneous injection. The therapeutically effective dose of a pharmaceutical varies from patient to patient and depends on factors such as the age and condition of the patient and the route of delivery. Such doses can be determined according to routine pharmacological procedures known to those skilled in the art. Factors that may affect the dose required to effectively treat a subject include, but are not limited to, the severity of the disease or disorder, previous treatments, the subject's general health and / or age, and other diseases present. Furthermore, treatment of a subject with a therapeutically effective amount of a therapeutic polynucleotide disclosed herein may include a single treatment or may include a series of treatments. The effective dose of a therapeutic polynucleotide disclosed herein used for treatment may increase or decrease over a particular course of treatment. Changes in dosage may result from and be evident from the results of the diagnostic assays described herein.

[0106] In some embodiments, a therapeutically effective amount or dose of a VWF targeting agent may be in the range of about 0.001 μg / kg or 0.01 μg / kg to about 250 mg / kg or 500 mg / kg body weight, with other ranges being about 0.01 μg / kg to 100 mg / kg body weight, about 0.01 μg / kg to 50 mg / kg body weight, about 0.1 μg / kg to 20 mg / kg body weight, about 0.1 μg / kg to 10 mg / kg body weight, about 1 μg / kg These dosages include, but are not limited to, about 1 μg / kg to 100 mg / kg body weight, about 1 μg / kg to 50 mg / kg body weight, about 10 μg / kg to 100 mg / kg body weight, about 10 μg / kg to 50 mg / kg body weight, about 20 μg / kg to 100 mg / kg body weight, about 20 μg / kg to 50 mg / kg body weight, about 1 mg / kg to 100 mg / kg body weight, about 1 mg / kg to 50 mg / kg body weight, or about 20 mg / kg to 50 mg / kg body weight. One of ordinary skill in the art will appreciate that certain factors can influence the dosage required to effectively treat a subject, including, but not limited to, the severity of the disease or disorder, previous treatments, the general health and / or age of the subject, and other diseases present.

[0107] In some embodiments, the pharmaceutical composition may be administered to a subject in need thereof in a single dose. A single dose of BT200 may be administered in the following amounts: 0.1 mg, 0.2 mg, 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 10.0 mg, 11.0 mg, 12.0 mg, 13.0 mg, 14.0 mg, 15.0 mg, 16.0 mg, 17.0 mg, 18.0 mg, 19.0mg, 20.0mg, 21.0mg, 22.0mg, 23.0mg, 24.0mg, 25.0mg, 26.0mg, 27.0mg, 28.0mg, 29.0mg, 30.0mg, 31.0mg, 32.0mg , 33.0mg, 34.0mg, 35.0mg, 36.0mg, 37.0mg, 38.0mg, 39.0mg, 40.0mg, 41.0mg, 42.0mg, 43.0mg, 44.0mg, 45.0mg, 46.0mg , 47.0mg, 48.0mg, 49.0mg, 50.0mg, 51.0mg, 52.0mg, 53.0mg, 54.0mg, 55.0mg, 56.0mg, 57.0mg, 58.0mg, 59.0mg, 60.0m g, 61.0mg, 62.0mg, 63.0mg, 64.0mg, 65.0mg, 66.0mg, 67.0mg, 68.0mg, 69.0mg, 70.0mg, 71.0mg, 72.0mg, 73.0mg, 74.0m g, 75.0 mg, 76.0 mg, 77.0 mg, 78.0 mg, 79.0 mg, 80.0 mg, 81.0 mg, 82.0 mg, 83.0 mg, 84.0 mg, 85.0 mg, 86.0 mg, 87.0 mg, 88.0 mg, 89.0 mg, 90.0 mg, 91.0 mg, 92.0 mg, 93.0 mg, 94.0 mg, 95.0 mg, 96.0 mg, 97.0 mg, 98.0 mg, 99.0 mg, or 100.0 mg.

[0108] In one preferred embodiment, a single dose of BT200 is about 1.0 mg to 10.0 mg, or about 1.0 mg to 6.0 mg. In some embodiments, the pharmaceutical composition may be administered to a subject in need thereof in multiple doses. The administration schedule provided herein is safe and effective for preventing bleeding. As a non-limiting example, a patient may be treated with the VWF targeting agent once a week. It will also be understood that the effective dose of the agent used in treatment may increase or decrease over a specific course of treatment. The agents of the present disclosure may be administered simultaneously or separately.

[0109] In one preferred embodiment, a multiple dose regimen is provided that includes an initial loading dose of BT200 and successive maintenance doses of BT200. The initial loading and maintenance doses may range from, but are not limited to, 0.1 mg to 10.0 mg of BT200, or 1.0 mg to 6.0 mg of BT200.

[0110] As a non-limiting example, BT200 may be administered at 0.1 mg, 0.2 mg, 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 3.5 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5 mg, 7.0 mg, 8.0 mg, 9.0 mg, 10.0 mg, 15 mg, or 20 mg. In some embodiments, BT200 may be administered at 3.0 mg, 6.0 mg, 9.0 mg, or 10.0 mg.

[0111] In some embodiments, the VWF targeting agent or pharmaceutical formulation thereof may be administered to a patient in need thereof about every day, about every other day, about every 3 days, about every 4 days, about every 5 days, about every 6 days, about every 7 days, about every 8-10 days, about every 11-14 days, or about every 3 weeks. In one embodiment, the VWF agent or pharmaceutical formulation thereof may be administered about every 7 days.

[0112] In some examples, the VWF targeting agent or pharmaceutical formulation thereof can be administered as a single dose. In other examples, administration of the VWF targeting agent or pharmaceutical formulation thereof can continue for about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 2 months, about 3-4 months, about 4-6 months, or about 1 year. In some examples, administration of the VWF agent or pharmaceutical formulation thereof can be about every 7 days for about 5 weeks. In certain embodiments, administration can be intermittent, for example, after about 4 weeks or after about 5 weeks. As a non-limiting example, a subject in need thereof may be treated once a week for about 5 weeks, followed by treatment about 3 to 4 times over several years. In some embodiments, the VWF agent or pharmaceutical formulation thereof can be administered intermittently to a subject to maintain vascular patency or to maintain VWF at a particular level. Use of administration schedules and methods in combination with other bleeding prevention therapies is included.

[0113] According to the present disclosure, the VWF targeting agent may be administered every other day, every three days, every five days, once a week, or once every two weeks. In a preferred embodiment, the VWF targeting agent may be administered with at least one initial loading dose and at least one maintenance dose. The initial loading dose and the maintenance dose may be the same or different. As a non-limiting example, the VWF targeting agent or pharmaceutical formulation thereof may be administered with two initial loading doses and three maintenance doses every seven days.

[0114] Equivalence and Scope Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments given the disclosure set forth herein. The scope of the present disclosure is not intended to be limited to the above description, but is instead set forth in the appended claims.

[0115] In the claims, unless indicated to the contrary or otherwise clear from the context, articles such as "a," "an," and "the" can mean one or more. A claim or description including "or" between one or more elements of a group is deemed to be satisfied if one, more than one, or all of the group elements are present in, employed in, or otherwise relevant to a given product or process, unless indicated to the contrary or otherwise clear from the context. The present disclosure includes embodiments in which exactly one element of a group is present in, employed in, or otherwise relevant to a given product or process. The present disclosure includes embodiments in which multiple group elements, or the entire group element, are present in, employed in, or otherwise relevant to a given product or process.

[0116] It is also noted that the term "comprising" is intended to be open, allowing but not requiring the inclusion of additional elements or steps. Thus, when the term "comprising" is used herein, the term "consisting of" is also encompassed and disclosed.

[0117] Where ranges are given, the endpoints are included. Furthermore, unless otherwise indicated, or otherwise clear from the context and the understanding of one of ordinary skill in the art, it should be understood that values ​​expressed as ranges can assume any specific value or subrange within the ranges set forth in different embodiments of the present disclosure, down to one-tenth of the unit of the lower limit of the range, unless otherwise clear from the context.

[0118] Furthermore, it should be understood that any particular embodiment of the present disclosure that is prior art may be expressly excluded from any one or more of the claims. Because such embodiments are deemed known to those of ordinary skill in the art, they may be excluded even if the exclusion is not expressly stated herein. Any particular embodiment of the compositions of the present disclosure (e.g., any antibiotic, therapeutic agent, or active ingredient, any method of manufacture, any method of use, etc.) may be excluded from any one or more claims for any reason, whether related to the existence of prior art or not.

[0119] The words used are words of description rather than of limitation, and it is to be understood that changes may be made within the purview of the appended claims without departing from the true scope and spirit of the present disclosure in its broader aspects.

[0120] While the present disclosure has been described at some length and in some detail with respect to several described embodiments, it is not intended to be limited to any such details or embodiments or to any particular embodiment, but rather should be construed with reference to the appended claims so as to provide the broadest possible interpretation of such claims in light of the prior art, and therefore so as to effectively encompass the intended scope of the present disclosure.

[0121] Example Example 1: Administration timeframe of BT200 to treat bleeding disorders Blood levels of factor VIII and VWF were measured in healthy volunteers after a single dose of BT200 at doses ranging from 0.18 mg to a maximum of 48 mg. One week after administration, blood levels of factor VIII and VWF antigen increased in a dose- and time-dependent manner (as shown in Table 3 (factor VIII) and Table 4 (VWF antigen)). In the description columns of Tables 3 and 4, the description includes the cohort number, the administered treatment, and the patient identifier. For example, "1-BT200-A" refers to patient A in cohort 1 who received BT200, and "1-Control-A" refers to patient A in the control group.

[0122] Table 3-1

[0123] Table 3-2

[0124] Table 3-3

[0125] Table 3-4

[0126] Table 3-5

[0127] Table 3-6

[0128] Table 3-7

[0129] Table 3-8

[0130] Table 3-9

[0131] Table 3-10

[0132] Table 3-11

[0133] Table 3-12

[0134] Table 3-13

[0135] Table 4-1

[0136] Table 4-2

[0137] Table 4-3

[0138] Table 4-4

[0139] Table 4-5

[0140] Table 4-6

[0141] Table 4-7

[0142] [Table 4-8]

[0143] [Table 4-9]

[0144] [Table 4-10]

[0145] [Table 4-11]

[0146] [Table 4-12]

[0147] [Table 4-13]

[0148] VWF function was also tested in treated individuals. No effect was observed compared to untreated individuals in three different activity tests: a multiplate aggregometer, a platelet function analyzer, and an ELISA for the free A1 domain of VWF. Factor VIII function was also increased in BT200-treated volunteers.

[0149] Results in healthy volunteers show that a lower dose (0.6 mg BT200) approximately doubles baseline FVIII activity 48 hours after administration and maintains nearly half of that increase over one week after administration. However, over the same period, no effect on VWF function was observed using the PFA-100® assay, a sensitive functional assay that uses undiluted whole blood.

[0150] The results also show that a 10-fold higher dose of BT200 (6 mg) maintains the doubling of baseline FVIII over two weeks after a single dose, without any evidence of the suppression of VWF function observed in the PFA-100® assay.

[0151] These observations indicate that BT200 can enhance VWF / FVIII levels in a dose-dependent manner. The elimination half-life of BT200 in healthy volunteers after a single dose was approximately 5-12 days, indicating that BT200 has a long half-life after subcutaneous injection and is well tolerated. No off-target adverse effects were observed with BT200 administration.

[0152] Coadministration of BT200 and desmopressin showed an additive effect on the levels of VWF and FVIII (shown in Figure 1) in the blood. Example 2: Individualized Dose Adjustment for Dose Response in Patients A diverse set of up to 25 patients with severe congenital hemophilia A without inhibitors, mild-to-moderate hemophilia A, heterozygous carriers of hemophilia A with subnormal FVIII levels, type 1 VWD, "Vicenza," or type 2b VWD will be enrolled in the study to evaluate dose titration and dose response.

[0153] Patients receive 3 mg of BT200 via subcutaneous (SC) injection on days 1, 4, and 7 (± 2 days). The dose of BT200 is then adjusted by 3-9 mg on days 14, 21, and 28 depending on the patient's bleeding disorder. FVIII activity is measured in patients with hemophilia A or type 1 VWD. Platelet count and / or FVIII activity are measured in patients with type 2b VWD.

[0154] Five patients with type 2b VWD (three men and two women) (Table 5) received 3 mg of BT200 on days 1 and 4, followed by weekly doses of 6–9 mg of BT200 (days 7, 14, 21, and 28). The median age of the patients was 61 years (range, 24–72 years). Four of the five patients presented with thrombocytopenia, and two patients were receiving regular recombinant VWF replacement therapy for recurrent severe bleeding. Efficacy was measured by VWF parameters, FVIII activity, and platelet counts before, during, and after treatment, as well as other clinical outcome parameters. Statistical analysis was performed using Friedman ANOVA.

[0155] [Table 5]

[0156] These results demonstrate that clinically meaningful responses occurred within 4 days of the first subcutaneous injection of BT200 (initial dose 3 mg of BT200). Platelet counts increased from a median of 60 at baseline to 159 / nL at day 28 (p=0.012), representing a maximum four-fold increase in all thrombocytopenic patients, with normalization in three-quarters of these patients (Figure 2). All thrombocytopenic patients responded with increased platelet counts 96 hours after the first dose of BT200. FVIIIc plasma levels doubled from 67% (44-91%) to 134% (114-200%) (p<0.001), normalizing in patients with subnormal FVIIIc activity (from 44% at baseline to 135% one week after the final dose). This was reflected by a uniformly prolonged activated partial thromboplastin time (aPTT-FS) reduction from 43 seconds to 32 seconds (p = 0.002) (Figure 3) and increased thrombin generation. BT200 administration increased circulating VWF antigen levels from 64% (32-106%) to 143% (103-351%) (p < 0.001) (Figure 4A). VWF collagen-binding activity (VWF:CBA) increased 2-4 fold in all patients, while VWF ristocetin cofactor (VWF:RCo) activity and VWF:GpIbM activity increased 2-3 fold in all thrombocytopenic patients, but only slightly in one patient without thrombocytopenia (all p < 0.05 for n = 5) (Figure 4B). The increased ristocetin BT200 was very well tolerated without any associated adverse effects.

[0157] These clinical observations indicate that BT200 specifically corrects the underlying pathophysiology of type 2b VWD, rapidly and robustly increasing platelet counts in patients with thrombocytopenia and elevating VWF and FVIIIc in all patients. It is hypothesized that BT200 may potentially benefit patients with type 2b VWD by increasing circulating VWF and FVIII levels in all patients and increasing platelet counts in patients with thrombocytopenia.

[0158] Hemophilia A patients were treated with BT200 on the same dosing schedule and showed increased FVIII activity (Figure 5). These results demonstrate that BT200 has a long half-life of 7-12 days. BT200 can induce not only a sustained increase in VWF levels and activity, but also an increase in FVIII levels and activity, as measured by aPTT shortening and increased thrombin generation.

[0159] Example 3: BT200 increases the half-life of FVIII therapy Patients were treated with FVIII therapy (Refacto AF / 3 patients, Elocta / 1 patient, Afstyla / 2 patients, Kovaltry / 1 patient, Advate / 1 patient). The half-lives of FVIII therapy before BT200 treatment were based on historical values ​​known in the art. Patients received a split loading dose and weekly doses followed by a loading dose (Table 6). The half-life of each FVIII therapy in each patient after BT200 treatment was measured 1 month after BT200 treatment. All FVIII values ​​were generated by chromogenic assay (patients 014, 017, 020-024) or one-stage clotting assay (patient 027). The mean increase was 3.1 (median = 2.8) (Table 6). These observations suggest that BT200 can increase the half-life of nearly all commercially available FVIII products.

[0160] [Table 6-1]

[0161] [Table 6-2]

Claims

1. A pharmaceutical composition for treating an inherited bleeding disorder in a subject, the pharmaceutical composition comprising a VWF targeting agent.

2. 2. The pharmaceutical composition of claim 1, wherein the inherited bleeding disorder is acquired platelet function deficiency, congenital platelet function deficiency, disseminated intravascular coagulation (DIC), prothrombin deficiency, fibrinogen deficiency, FV deficiency, FVII deficiency, FX deficiency, FXI deficiency (hemophilia C), FXIII deficiency, combined FV and FVIII deficiency (F5F8D), VKCFD, Glanzmann thrombasthenia, hemophilia A, hemophilia B, immune thrombocytopenic purpura (ITP), von Willebrand disease (VWD) type 1, von Willebrand disease (VWD) type 2, and von Willebrand disease (VWD) type 3.

3. 3. The pharmaceutical composition of claim 2, wherein the inherited bleeding disorder is hemophilia A, mild hemophilia, moderate hemophilia, severe hemophilia, VWD type 1, VWD type 1 Vicenza subtype, VWD type 2a, VWD type 2b, VWD type 2b with thrombocytopenia, VWD type 2m, VWD type 2n, or VWD type 3.

4. 2. The pharmaceutical composition of claim 1, wherein the VWF targeting agent is a VWF binding agent selected from the group consisting of an antibody, a nanobody, a peptide, an oligonucleotide, an siRNA, a microRNA, a synthetic polynucleotide, and a small molecule.

5. 5. The pharmaceutical composition of claim 4, wherein the VWF binding agent is a synthetic polynucleotide selected from the group consisting of SEQ ID NO: 3, BT99 (SEQ ID NO: 4), BT100 (SEQ ID NO: 5), BT200 (SEQ ID NO: 6), ARC15105 (SEQ ID NO: 7), and ARC1779 (SEQ ID NO: 8) and variants thereof.

6. The pharmaceutical composition of claim 5 , wherein the VWF binding agent is BT200 (SEQ ID NO: 6) or a variant thereof.

7. 7. The pharmaceutical composition of claim 6, wherein BT200 increases VWF levels and activity, FVIII levels and activity, and / or platelet count in blood.

8. 7. The pharmaceutical composition of claim 6, wherein BT200 is administered to the subject at a dose ranging from 0.1 mg to 48.0 mg, or from 0.1 mg to 20.0 mg, or from 1.0 mg to 10 mg.

9. 9. The pharmaceutical composition of claim 8, wherein BT200 is administered to the subject at a dose ranging from 0.6 mg to 6.0 mg.

10. The pharmaceutical composition of claim 6 , wherein the VWF binding agent is administered to the subject via subcutaneous injection.

11. 11. The pharmaceutical composition of claim 10, wherein the VWF binding agent is administered to the subject in multiple doses, each dose being administered once every other day, or once every three days, or once every five days, or once a week, or once every two weeks.

12. The pharmaceutical composition according to any one of claims 1 to 11, wherein said treatment of said inherited bleeding disorder is a therapeutic or prophylactic treatment.

13. The pharmaceutical composition of claim 3, wherein the VWF targeting agent is administered in combination with coagulation factor replacement therapy, and the coagulation factor replacement is a plasma-derived FVIII / VWF concentrate, a recombinant FVIII preparation, or a recombinant VWF preparation.

14. A pharmaceutical composition for preventing a chronic bleeding condition and / or spontaneous bleeding in a subject, the pharmaceutical composition comprising a VWF targeting agent.

15. The pharmaceutical composition of claim 14, wherein the VWF targeting agent is a VWF binding agent selected from the group consisting of an antibody, a nanobody, a peptide, an oligonucleotide, an siRNA, a microRNA, a synthetic polynucleotide, and a small molecule.

16. The pharmaceutical composition of claim 15, wherein the VWF binding agent is a synthetic polynucleotide comprising a PEGylated nucleic acid.

17. 17. The pharmaceutical composition of claim 16, wherein the VWF binding agent is BT200 (SEQ ID NO: 6), or a variant thereof.

18. 18. The pharmaceutical composition of claim 17, wherein BT200 is administered in a dose ranging from 1.0 mg to 10.0 mg, or alternatively in a dose ranging from 1.0 mg to 6.0 mg.

19. A pharmaceutical composition for blocking VWF clearance in the blood, comprising a VWF targeting agent that is a synthetic polynucleotide that includes a PEGylated moiety.

20. 20. The pharmaceutical composition of claim 19, wherein the VWF targeting agent is BT200 (SEQ ID NO: 6), or a variant thereof.

21. 21. The pharmaceutical composition of claim 20, wherein BT200 is provided in an amount ranging from 0.6 mg to 6.0 mg, or from 1.0 mg to 6.0 mg, or from 1.0 mg to 10.0 mg.

22. 22. The pharmaceutical composition of claim 21, wherein BT200 increases VWF levels in the blood.

23. A pharmaceutical composition for increasing FVIII levels in the blood of a subject, the pharmaceutical composition comprising a VWF targeting agent that is a synthetic polynucleotide that includes a PEGylated moiety.

24. 24. The pharmaceutical composition of claim 23, wherein the subject has been diagnosed with hemophilia A, VWD type 1, VWD type 2, or VWD type 3.

25. 25. The pharmaceutical composition of claim 24, wherein the VWF targeting agent is BT200 (SEQ ID NO: 6), or a variant thereof.

26. 26. The pharmaceutical composition of claim 25, wherein BT200 increases FVIII coagulation activity.

27. A pharmaceutical composition for increasing the number of platelets in the blood of a patient, the pharmaceutical composition comprising BT200 (SEQ ID NO: 6), said patient having a low platelet count (thrombocytopenia).

28. 28. The pharmaceutical composition of claim 27, wherein the thrombocytopenia is associated with a genetic disorder causing low platelet counts, an enlarged spleen that holds abnormal platelets, an adverse reaction to a drug, an autoimmune disease, or a viral infection.

29. 29. The pharmaceutical composition of claim 28, wherein the disorder is type 2a VWD, type 2b VWD with thrombocytopenia, type 2b VWD, type 2m VWD, or type 2n VWD.

30. A pharmaceutical composition for the treatment of an inherited bleeding disorder in a patient, comprising BT200 as a VWF binding agent, The treatment, a) assessing the inherited bleeding disorder in the patient and baseline coagulation function in the patient; b) determining an optimal dose of BT200 using the evaluation of step a) for initial treatment; and c) providing weekly doses of BT200 following one week of treatment in said patient with an initial dose of BT200.

31. 31. The pharmaceutical composition of claim 30, wherein the inherited bleeding disorder can be hemophilia A, severe hemophilia, VWD type 1, VWD type 2a, VWD type 2b, VWD type 2m, VWD type 2n, or VWD type 3.

32. The pharmaceutical composition of claim 31 , wherein the assessment comprises FVIII activity in blood, VWF antigen levels and / or platelet count.

33. 32. The pharmaceutical composition of claim 31, wherein the patient is treated with clotting factor replacement.

34. A VWF targeting agent for use in the treatment of an inherited bleeding disorder, the VWF targeting agent being a synthetic polynucleotide comprising the sequence of SEQ ID NO:

6.

35. Use of a VWF targeting agent in the manufacture of a pharmaceutical for the treatment of an inherited bleeding disorder, wherein the VWF targeting agent is a synthetic polynucleotide comprising the sequence of SEQ ID NO:6.